Short-term vision changes after eye electrical stimulation in retinitis pigmentosa and related diseases
Looks at whether short-term vision changes after electrical eye stimulation can be measured.
Plain-language title generated from the registry record
Registry title: Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance
Key facts
- Where
- Frankfurt am Main, GermanySee the site
Where in Germany
- Augenzentrum Frankfurt Prof. Koch GmbHFrankfurt am Main, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Okuvision GmbH
- Trial code
- NCT07548944
- Record updated
- 1 May 2026
- Original description
Retinitis pigmentosa and similar degenerative diseases of the retina lead to progressive loss of vision. TES therapy with the CE-marked OkuStim® System is a treatment approved in the EU for slowing the progression of the disease. Patients increasingly report short-term subjective improvements in vision, which have not yet been systematically investigated. This exploratory study is conducted to determine whether these subjective short-term effects can be measured, and therefore also be quantified, by objective tests.Read full original descriptionShow less
Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation (TES) on Visual Performance in Patients With Retinitis Pigmentosa and Similar Retinal Diseases
Retinitis pigmentosa and similar degenerative diseases of the retina lead to progressive loss of vision. TES therapy with the CE-marked OkuStim® System is a treatment approved in the EU for slowing the progression of the disease. Patients increasingly report short-term subjective improvements in vision, which have not yet been systematically investigated. This exploratory study is conducted to determine whether these subjective short-term effects can be measured, and therefore also be quantified, by objective tests.
Inclusion: Adult patients (≥ 18 years) with clinically diagnosed retinitis pigmentosa (RP) or other similar degenerative retinal disease; Current treatment with TES using the OkuStim® System within the intended purpose; Subjective perception of short-term effects after TES treatment; Ability and willingness to give informed consent.
Exclusion: Presence of other eye diseases (e.g., cataract, glaucoma, macular degeneration) that, in the opinion of the investigator, compromise or confound study assessments; Cognitive, psychological, or linguistic limitations that prevent informed consent or proper study participation; Simultaneous participation in other clinical studies that could influence the results of the study; Severe comorbidities that could compromise patient safety or study conduct.